Denali Therapeutics Inc. which can be found using ticker (DNLI) have now 14 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between 105 and 30 calculating the mean target price we have $58.71. Now with the previous closing price of $31.58 this would imply there is now a potential upside of 85.9%. It’s also worth noting that there is a 50 day moving average of $25.26 and the 200 moving average now moves to $28.77. The company has a market capitalization of 4.31B. The stock price is currently at: 31.51 USD
The potential market cap would be $8,018,938,553 based on the market consensus.
USD
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 0.79 and a -18.09% return on assets.
